• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2020 Fiscal Year Final Research Report

Development of novel antiacid bacterial immunotherapy based on mucosal immune response

Research Project

  • PDF
Project/Area Number 19K22645
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 54:Internal medicine of the bio-information integration and related fields
Research InstitutionNational Institutes of Biomedical Innovation, Health and Nutrition

Principal Investigator

IIJIMA NORIFUMI  国立研究開発法人医薬基盤・健康・栄養研究所, 医薬基盤研究所 細胞核輸送ダイナミクスプロジェクト, サブプロジェクトリーダー (40612552)

Project Period (FY) 2019-06-28 – 2021-03-31
Keywords粘膜免疫増強
Outline of Final Research Achievements

Anti-acid bacilli such as Mycobacterium tuberculosis and Leprosy are capable of parasitizing and reproducing in macrophages, the cells responsible for immunity, and are therefore highly virulent and can survive in the body for a long time. Therefore, if they cannot be treated with existing antibacterial drugs, the growth of anti-acid bacilli can become uncontrollable, resulting in life-threatening consequences. Therefore, we propose a research plan that will serve as the basis for a new immunotherapy against multidrug-resistant acid-fast bacteria, focusing on the reinforcement of immune defense in mucosal tissues instead of conventional chemotherapies. The goal of this project is to provide the basis for a new therapeutic platform against multidrug-resistant acid-fast bacteria in preparation for a pandemic.

Free Research Field

粘膜免疫

Academic Significance and Societal Importance of the Research Achievements

抗酸菌の一つである結核菌は世界10大死因の一つに数えられ、2016年には世界中で1,040万人が結核に罹患し、170万人が結核で死亡している。抗結核薬を長期間投与することにより、結核菌を駆逐することが可能であるが、多剤耐性結核菌(MDR) や広範囲薬剤耐性結核菌(XDR)に対しては、効果を発揮しない例が増加している。最も致命的なのは、すべての抗結核薬に耐性の結核菌の将来的な蔓延である。
本研究では、耐性菌を生み出す化学療法ではなく、粘膜組織の免疫増強効果を目的とした免疫療法のプラットフォームの構築を検討することで、今後の多剤耐性菌にも対処できる治療方法の新しい方向性を示すことに成功した。

URL: 

Published: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi